Coya Therapeutics, Inc.
A Houston-based biotech developing therapies that boost the body's regulatory T cells — the immune system's peacekeepers — to fight the inflammation behind neurodegenerative diseases like Parkinson's, Alzheimer's and ALS. Founder Dr. Howard Berman started the company in 2020 after his father's battle with dementia, teaming up with neurologist Dr. Stanley Appel. Its name echoes the earlier venture Berman co-founded, Nicoya Health.
Bought 11.0K
Granted 17.6K · Bought 10.0K
Bought 10.0K
Bought 10.0K
Bought 10.0K
Bought 8.8K
Bought 2.7K
Bought 2.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Lee AnnDirector · 3 transactions | — | 34.0Kas of Aug 2023 | — | 11.0K | — |
| Goldstein Dov A MDDirector · 2 transactions | — | 27.6Kas of Aug 2025 | 17.6K | 10.0K | — |
| Hepner AdrianChief Medical Officer · 1 transaction | — | 10.0Kas of Jan 2023 | — | 10.0K | — |
| Swaminathan ArunChief Executive Officer, Director · 2 transactions | — | 10.0Kas of Nov 2024 | — | 10.0K | — |
| Villalobos AnabellaDirector · 1 transaction | — | 10.0Kas of Jan 2023 | — | 10.0K | — |
| Snyder David SChief Financial Officer · 2 transactions | — | 8.8Kas of Nov 2024 | — | 8.8K | — |
| Grossman FredChief Medical Officer · 1 transaction | — | 2.7Kas of Nov 2024 | — | 2.7K | — |
| Garren HidekiDirector · 1 transaction | — | 2.0Kas of Jan 2023 | — | 2.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +64.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.